PRINCETON, N.J.--(BUSINESS WIRE)--PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6) today announced plans to expedite the development of its new class of cinnamon-derived ‘polyphenolic’ compounds, which possess unique antioxidant and insulin enhancing qualities, distinct from existing classes of drugs for diabetes.
